SCHEMBL662610

SCHEMBL662610

CCCc1ccc(O)c(-c2cc(CCC)ccc2O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 1.00
CNR2 P34972 2/20 1.00
ALOX5 P09917 3/20 0.68
GABRA1 P14867 2/20 0.57
GABRB2 P47870 2/20 0.57
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
GAA P10253 2/20 0.50
MAPT P10636 2/20 0.50
MEN1 O00255 1/20 0.50
ALDH2 P05091 1/20 0.50
AKR1B1 P15121 1/20 0.50
HPGD P15428 1/20 0.50
PPARG P37231 1/20 0.50
KMT2A Q03164 1/20 0.50
PPARD Q03181 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
BACE1 P56817 4/20 0.49
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29380189 1.00 CNR1 (1.00) CNR1CNR2ALOX5GABRA1GABRB2
SCHEMBL25383045 0.94 CNR1 (0.88) CNR1CNR2ALOX5GABRA1GABRB2
Sulfur Dioxide SCHEMBL20526191 0.92 CNR1 (0.85) CNR1CNR2ALOX5GABRA1GABRB2
SCHEMBL721719 0.90 CNR1 (0.81) CNR1CNR2ALOX5GABRA1GABRB2
SCHEMBL723543 0.87 CNR1 (0.77) CNR1CNR2ALOX5KDM4EALDH1A1
SCHEMBL8940661 0.86 CNR1 (0.73) CNR1CNR2ALOX5GABRA1GABRB2
SCHEMBL7747447 0.86 GABRA1 (0.77) CNR1CNR2ALOX5GABRA1GABRB2
SCHEMBL7080953 0.85 CNR1 (0.72) CNR1CNR2ALOX5GABRA1GABRB2
SCHEMBL167391 0.85 CNR1 (0.72) CNR1CNR2ALOX5GABRA1GABRB2
SCHEMBL12881959 0.84 CNR1 (0.71) CNR1CNR2ALOX5GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022226857-A1 WET DRESSING FOR TATTOO COLOR PROTECTION AND USING METHOD THEREFOR 美丽康生技股份有限公司 2022-11-03 WO claimed
EP-3763396-A1 METHOD FOR COLOR MAINTENANCE AND ENHANCEMENT OF TATTOO MLK Bioscience Co., Ltd. (TW) 2021-01-13 EP claimed
EP-2794534-B1 PROCESSES FOR MAKING MAGNOLOL AND DERIVATIVES THEREOF COLGATE PALMOLIVE CO (US) 2016-11-30 EP claimed
EP-2794535-B1 PROCESSES FOR MAKING MAGNOLOL ANALOGS COLGATE PALMOLIVE CO (US) 2016-04-20 EP claimed
US-9045397-B2 Processes for making magnolol analogs COLGATE-PALMOLIVE COMPANY (US) 2015-06-02 US claimed
US-9000231-B2 Processes for making magnolol and derivatives thereof COLGATE-PALMOLIVE COMPANY (US) 2015-04-07 US claimed
US-20140357902-A1 PROCESSES FOR MAKING MAGNOLOL AND DERIVATIVES THEREOF COLGATE-PALMOLIVE COMPANY (US) 2014-12-04 US claimed
US-20140343328-A1 PROCESSES FOR MAKING MAGNOLOL ANALOGS COLGATE-PALMOLIVE COMPANY (US) 2014-11-20 US claimed
EP-2794534-A1 PROCESSES FOR MAKING MAGNOLOL AND DERIVATIVES THEREOF Colgate-Palmolive Company (US) 2014-10-29 EP claimed
WO-2013095361-A1 PROCESSES FOR MAKING MAGNOLOL AND DERIVATIVES THEREOF COLGATE-PALMOLIVE COMPANY (US) 2013-06-27 WO claimed
EP-4262528-B1 DEVICE AND METHOD FOR CONTINUOUS EVEN APPLICATION OF COMPOSITION TO SKIN KENVUE BRANDS LLC (US) 2026-02-18 EP disclosed
US-12472336-B2 System and method for selective application of cosmetic composition to impart undereye brightening KENVUE BRANDS LLC (US) 2025-11-18 US disclosed
EP-3389595-B1 COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC ACID HAVING TWO OR MORE ACID DISSOCIATION CONSTANTS OREAL (FR) 2025-11-05 EP disclosed
EP-4234042-B1 MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR POLA CHEM IND INC (JP) 2025-08-13 EP disclosed
US-12358008-B2 Device for supplying a composition to a pressurized deposition system KENVUE BRANDS LLC (US) 2025-07-15 US disclosed
WO-2011102001-A1 COSMETIC COMPOSITION L'OREAL (FR) 2011-08-25 WO disclosed
EP-2042153-A1 SKIN COSMETIC Kao Corporation (JP) 2009-04-01 EP disclosed
US-20090053152-A1 SKIN COSMETIC KAO CORPORATION (JP) 2009-02-26 US disclosed
JP-2006325441-A METHOD FOR PRODUCING 2,2'-DIHYDROXY-5,5'-DIPROPYLBIPHENYL T HASEGAWA CO LTD 2006-12-07 JP disclosed
JP-2006325441-A METHOD FOR PRODUCING 2,2'-DIHYDROXY-5,5'-DIPROPYLBIPHENYL T HASEGAWA CO LTD 2006-12-07 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357902-A1 PROCESSES FOR MAKING MAGNOLOL AND DERIVATIVES THEREOF ADRB2, ADRB1, CYP4B1 CNR1 1533/4885CNR2 446/4885ALOX5 128/4885
US-20090053152-A1 SKIN COSMETIC TYR, MC1R, MC3R CNR1 2689/4885CNR2 3120/4885ALOX5 1455/4885
US-20140343328-A1 PROCESSES FOR MAKING MAGNOLOL ANALOGS REN, ADRB1, ADRB2 CNR1 2929/4885CNR2 2107/4885ALOX5 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.